Tuesday, August 3, 2010: 10:00 AM
Seacliff AB (Hyatt Regency San Francisco)
E.Coli fermentation is a workhorse for the production of recombinant proteins as early stage vaccine candidates in Bioprocess Research and Development at Sanofi Pasteur, (BRD Toronto). To ensure desired performance with exceptional efficiency, E.Coli fermentation is enhanced via many innovative technologies including Design of Experiment (DoE), Process Analytical Technology (PAT), Quality by Design (QbD), Supervisory Control and Cata Acquisition (SCADA), micro-reactors, and neural network modeling.
An illustration of how E.Coli fermentation in BRD Toronto has benefited from innovative technologies will be presented; this will include the identification of design and control spaces, automated feeding and induction strategies, high throughput process parameter screening using micro-reactors, soft-sensor for biomass monitoring, and live dashboard reporting of pre-defined key performance index (KPI). These approaches have contributed to the control of product yield and quality.
On-going efforts on enabling technologies will also be introduced, in addition to our vision for achieving performance excellence in fermentation.